{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:06:11Z","timestamp":1790687171111,"version":"4.1.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70113307"],"award-info":[{"award-number":["70113307"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["BE 5877\/2-1"],"award-info":[{"award-number":["BE 5877\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.pharmthera.2021.107931","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T04:05:19Z","timestamp":1624421119000},"page":"107931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions"],"prefix":"10.1016","volume":"228","author":[{"given":"Marcel","family":"Renn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Bartok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayk","family":"Behrendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharmthera.2021.107931_bb0010","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01113-18","article-title":"Moving forward: Recent developments for the Ferret biomedical research model","volume":"9","author":"Albrecht","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2021.04.001","article-title":"A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice","author":"de Alwis","year":"2021","journal-title":"Molecular Therapy: The Journal of the American Society of Gene Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107931_bb0020","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0025","first-page":"1","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","author":"Bao","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.immuni.2020.06.014","article-title":"Immune sensing mechanisms that discriminate self from altered self and foreign nucleic acids","volume":"53","author":"Bartok","year":"2020","journal-title":"Immunity"},{"issue":"6515","key":"10.1016\/j.pharmthera.2021.107931_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"issue":"6520","key":"10.1016\/j.pharmthera.2021.107931_bb0040","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107931_bb0045","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"issue":"6504","key":"10.1016\/j.pharmthera.2021.107931_bb0050","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1126\/science.abc3545","article-title":"Type III interferons disrupt the lung epithelial barrier upon viral recognition","volume":"369","author":"Broggi","year":"2020","journal-title":"Science"},{"issue":"6518","key":"10.1016\/j.pharmthera.2021.107931_bb0055","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.abd2985","article-title":"Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity","volume":"370","author":"Cantuti-Castelvetri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0060","article-title":"Fatal neuroinvasion of SARS-CoV-2 in K18-hACE2 mice is partially dependent on hACE2 expression","author":"Carossino","year":"2021","journal-title":"BioRxiv: The Preprint Server for Biology"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0065","series-title":"Advantages and limitations of commonly used nonhuman primate species in research and development of biopharmaceuticals","first-page":"379","author":"Cauvin","year":"2015"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0070","article-title":"Surgical mask partition reduces the risk of non-contact transmission in a golden Syrian hamster model for Coronavirus Disease 2019 (COVID-19)","author":"Chan","year":"2020","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0075","article-title":"Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: Implications for disease pathogenesis and transmissibility","author":"Chan","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107931_bb0080","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host & Microbe"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0085","first-page":"1","article-title":"A systematic review of neurological symptoms and complications of COVID-19","author":"Chen","year":"2020","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107931_bb0090","doi-asserted-by":"crossref","first-page":"108254","DOI":"10.1016\/j.celrep.2020.108254","article-title":"Furin inhibitors block SARS-CoV-2 spike protein cleavage to suppress virus production and cytopathic effects","volume":"33","author":"Cheng","year":"2020","journal-title":"Cell Reports"},{"issue":"26","key":"10.1016\/j.pharmthera.2021.107931_bb0095","doi-asserted-by":"crossref","first-page":"14695","DOI":"10.1073\/pnas.94.26.14695","article-title":"Development of an epithelium-specific expression cassette with human DNA regulatory elements for transgene expression in lung airways","volume":"94","author":"Chow","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/j.pharmthera.2021.107931_bb0100","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.ymthe.2017.07.003","article-title":"RIG-I activation protects and rescues from lethal influenza virus infection and bacterial superinfection","volume":"25","author":"Coch","year":"2017","journal-title":"Molecular Therapy"},{"issue":"6517","key":"10.1016\/j.pharmthera.2021.107931_bb0105","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1126\/science.370.6517.642","article-title":"\u2018A very, very bad look\u2019 for remdesivir","volume":"370","author":"Cohen","year":"2020","journal-title":"Science"},{"issue":"7830","key":"10.1016\/j.pharmthera.2021.107931_bb0110","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.pharmthera.2021.107931_bb0115","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0120","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nature Microbiology"},{"issue":"7830","key":"10.1016\/j.pharmthera.2021.107931_bb0125","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","article-title":"A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures","volume":"586","author":"Dinnon","year":"2020","journal-title":"Nature"},{"issue":"7830","key":"10.1016\/j.pharmthera.2021.107931_bb0130","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0135","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/s41467-021-21992-w","article-title":"Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model","volume":"12","author":"Driouich","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.virol.2015.03.017","article-title":"Ferret models of viral pathogenesis","volume":"479\u2013480","author":"Enkirch","year":"2015","journal-title":"Virology"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0145","article-title":"Characteristic and quantifiable COVID-19-like abnormalities in CT- and PET\/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis)","author":"Finch","year":"2020","journal-title":"BioRxiv"},{"issue":"6499","key":"10.1016\/j.pharmthera.2021.107931_bb0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107931_bb0155","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng1668","article-title":"Current issues in mouse genome engineering","volume":"37","author":"Glaser","year":"2005","journal-title":"Nature Genetics"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107931_bb0160","doi-asserted-by":"crossref","first-page":"F608","DOI":"10.1152\/ajprenal.00554.2020","article-title":"The novel STING antagonist H151 ameliorates cisplatin-induced acute kidney injury and mitochondrial dysfunction","volume":"320","author":"Gong","year":"2021","journal-title":"American Journal of Physiology. Renal Physiology"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0165","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","author":"Grein","year":"2020","journal-title":"New England Journal of Medicine."},{"issue":"6511","key":"10.1016\/j.pharmthera.2021.107931_bb0170","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107931_bb0175","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41591-020-0968-3","article-title":"Extrapulmonary manifestations of COVID-19","volume":"26","author":"Gupta","year":"2020","journal-title":"Nature Medicine"},{"issue":"7713","key":"10.1016\/j.pharmthera.2021.107931_bb0180","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41586-018-0287-8","article-title":"Targeting STING with covalent small-molecule inhibitors","volume":"559","author":"Haag","year":"2018","journal-title":"Nature"},{"issue":"6504","key":"10.1016\/j.pharmthera.2021.107931_bb0185","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107931_bb0190","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJMc2013400","article-title":"Transmission of SARS-CoV-2 in domestic cats","volume":"383","author":"Halfmann","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107931_bb0195","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","article-title":"A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies","volume":"182","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0200","article-title":"A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection","author":"Hassler","year":"2021","journal-title":"BioRxiv"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107931_bb0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107931_bb0210","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.tim.2004.08.008","article-title":"Cellular entry of the SARS coronavirus","volume":"12","author":"Hofmann","year":"2004","journal-title":"Trends in Microbiology"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0215","first-page":"1","article-title":"Characteristics of SARS-CoV-2 and COVID-19","author":"Hu","year":"2020","journal-title":"Nature Reviews Microbiology"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7169-5_1","article-title":"Generating genetically modified mice: a decision guide","volume":"1642","author":"Huijbers","year":"2017","journal-title":"Methods in Molecular Biology (Clifton, N.J.)"},{"issue":"28","key":"10.1016\/j.pharmthera.2021.107931_bb0225","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107931_bb0230","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201241","article-title":"Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling","volume":"217","author":"Israelow","year":"2020","journal-title":"The Journal of Experimental Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107931_bb0235","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1\u20137: Novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nature Reviews Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0240","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","article-title":"Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2","volume":"182","author":"Jiang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abf1906","article-title":"The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates","author":"Jones","year":"2021","journal-title":"Science Translational Medicine"},{"issue":"43","key":"10.1016\/j.pharmthera.2021.107931_bb0250","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107931_bb0255","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.chom.2020.03.023","article-title":"Infection and rapid transmission of SARS-CoV-2 in Ferrets","volume":"27","author":"Kim","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"6530","key":"10.1016\/j.pharmthera.2021.107931_bb0260","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107931_bb0265","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.cell.2020.09.049","article-title":"A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 Hamster model","volume":"183","author":"Kreye","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0270","doi-asserted-by":"crossref","DOI":"10.3390\/v13010132","article-title":"Neuroinvasion and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice","volume":"13","author":"Kumari","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0275","first-page":"1","article-title":"The type I interferon response in COVID-19: Implications for treatment","author":"Lee","year":"2020","journal-title":"Nature Reviews Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107931_bb0280","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.cell.2020.09.050","article-title":"A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice","volume":"183","author":"Leist","year":"2020","journal-title":"Cell"},{"issue":"6965","key":"10.1016\/j.pharmthera.2021.107931_bb0285","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0290","article-title":"Comparison of SARS-CoV-2 infections among 3 species of non-human primates","author":"Lu","year":"2020","journal-title":"BioRxiv"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107931_bb0295","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.3201\/eid2312.170798","article-title":"Avian influenza A(H7N2) virus in human exposed to sick cats, New York, USA, 2016","volume":"23","author":"Marinova-Petkova","year":"2017","journal-title":"Emerging Infectious Diseases"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107931_bb0300","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray","year":"2007","journal-title":"Journal of Virology"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107931_bb0305","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1073\/pnas.1517719113","article-title":"SARS-like WIV1-CoV poised for human emergence","volume":"113","author":"Menachery","year":"2016","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0310","first-page":"1","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","author":"Mercado","year":"2020","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107931_bb0315","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41564-019-0421-x","article-title":"Decoding type I and III interferon signalling during viral infection","volume":"4","author":"Mesev","year":"2019","journal-title":"Nature Microbiology"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107931_bb0320","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.cell.2021.03.026","article-title":"BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection","volume":"184","author":"Mills","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0325","article-title":"A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19","author":"Mitj\u00e0","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"0","key":"10.1016\/j.pharmthera.2021.107931_bb0330","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"0","author":"Monk","year":"2020","journal-title":"The Lancet Respiratory Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107931_bb0335","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0340","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.20-0762","article-title":"Evaluation of K18-hACE2 mice as a model of SARS-CoV-2 infection","author":"Moreau","year":"2020","journal-title":"The American Journal of Tropical Medicine and Hygiene"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107931_bb0345","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11248-007-9075-1","article-title":"Improving the generation of genomic-type transgenic mice by ICSI","volume":"16","author":"Moreira","year":"2007","journal-title":"Transgenic Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0350","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13073-015-0178-7","article-title":"Precision cancer mouse models through genome editing with CRISPR-Cas9","volume":"7","author":"Mou","year":"2015","journal-title":"Genome Medicine"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0355","article-title":"Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans","author":"Munnink","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0360","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2324-7","article-title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2","author":"Munster","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0365","article-title":"Mouse adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge [Preprint]","author":"Muruato","year":"2021","journal-title":"Microbiology"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0370","article-title":"Lethality of SARS-CoV-2 infection in K18 human angiotensin converting enzyme 2 transgenic mice","author":"Oladunni","year":"2020","journal-title":"BioRxiv"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107931_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/v12070779","article-title":"Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters","volume":"12","author":"Osterrieder","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0380","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1038\/s41467-020-19741-6","article-title":"Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission","volume":"11","author":"Peckham","year":"2020","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0385","first-page":"1","article-title":"Spike mutation D614G alters SARS-CoV-2 fitness","author":"Plante","year":"2020","journal-title":"Nature"},{"issue":"27","key":"10.1016\/j.pharmthera.2021.107931_bb0390","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1016\/j.pharmthera.2021.107931_bb0395","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101918118","article-title":"Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice","volume":"118","author":"Pymm","year":"2021","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0400","article-title":"Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection","author":"Rathnasinghe","year":"2020","journal-title":"BioRxiv: The Preprint Server for Biology."},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.0030005","article-title":"A mouse-adapted SARS-coronavirus causes disease and mortality in BALB\/c mice","volume":"3","author":"Roberts","year":"2007","journal-title":"PLoS Pathogens"},{"issue":"6494","key":"10.1016\/j.pharmthera.2021.107931_bb0410","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1126\/science.abb7314","article-title":"Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model","volume":"368","author":"Rockx","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","author":"Rogers","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0420","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41467-021-22580-8","article-title":"Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model","volume":"12","author":"Rosenke","year":"2021","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0425","article-title":"Eicosanoid signaling as a therapeutic target in middle-aged mice with severe COVID-19","author":"Roy Wong","year":"2021","journal-title":"BioRxiv: The Preprint Server for Biology"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(20)30089-6","article-title":"SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: An experimental transmission study","author":"Schlottau","year":"2020","journal-title":"The Lancet Microbe"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107931_bb0435","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3390\/vaccines8040584","article-title":"Cold-adapted live attenuated SARS-Cov-2 vaccine completely protects human ACE2 transgenic mice from SARS-Cov-2 infection","volume":"8","author":"Seo","year":"2020","journal-title":"Vaccines"},{"issue":"6494","key":"10.1016\/j.pharmthera.2021.107931_bb0440","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2","volume":"368","author":"Shi","year":"2020","journal-title":"Science"},{"issue":"7818","key":"10.1016\/j.pharmthera.2021.107931_bb0445","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"issue":"e20202135","key":"10.1016\/j.pharmthera.2021.107931_bb0450","article-title":"Neuroinvasion of SARS-CoV-2 in human and mouse brain","volume":"218","author":"Song","year":"2021","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107931_bb0455","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cell.2020.06.010","article-title":"Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment","volume":"182","author":"Sun","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107931_bb0460","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","article-title":"A mouse model of SARS-CoV-2 infection and pathogenesis","volume":"28","author":"Sun","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0465","first-page":"1","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","author":"Taylor","year":"2021","journal-title":"Nature Reviews Immunology"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107931_bb0470","first-page":"04.355842","article-title":"The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity","volume":"2020","author":"Thomson","year":"2020","journal-title":"BioRxiv"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107931_bb0475","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1128\/JVI.01702-06","article-title":"Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor","volume":"81","author":"Tseng","year":"2007","journal-title":"Journal of Virology"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107931_bb0480","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.immuni.2020.05.002","article-title":"Immunology of COVID-19: Current State of the Science","volume":"52","author":"Vabret","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0485","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2016.06.012","article-title":"Nanobodies\u00ae\u2020\u2020Nanobody is a registered trademark of Ablynx NV as inhaled biotherapeutics for lung diseases","volume":"169","author":"Van Heeke","year":"2017","journal-title":"Pharmacology & Therapeutics"},{"issue":"7853","key":"10.1016\/j.pharmthera.2021.107931_bb0490","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"issue":"6536","key":"10.1016\/j.pharmthera.2021.107931_bb0495","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1126\/science.abf4896","article-title":"Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets","volume":"371","author":"de Vries","year":"2021","journal-title":"Science"},{"issue":"7850","key":"10.1016\/j.pharmthera.2021.107931_bb0500","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41586-021-03312-w","article-title":"SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801","volume":"591","author":"Wahl","year":"2021","journal-title":"Nature"},{"issue":"10236","key":"10.1016\/j.pharmthera.2021.107931_bb0505","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"The Lancet"},{"key":"10.1016\/j.pharmthera.2021.107931_bb5000","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0510","article-title":"SARS-CoV-2 infection in the lungs of human ACE2 transgenic mice causes severe inflammation, immune cell infiltration, and compromised respiratory function","author":"Winkler","year":"2020","journal-title":"BioRxiv: The Preprint Server for Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107931_bb0515","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/irv.12687","article-title":"Improving immunological insights into the ferret model of human viral infectious disease","volume":"13","author":"Wong","year":"2019","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0520","article-title":"Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants","author":"Xu","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0525","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","author":"Yang","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107931_bb0530","first-page":"450","article-title":"Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection","volume":"57","author":"Yang","year":"2007","journal-title":"Comparative Medicine"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0535","article-title":"K18-hACE2 mice develop respiratory disease resembling severe COVID-19","author":"Yinda","year":"2020","journal-title":"BioRxiv: The Preprint Server for Biology"},{"issue":"6505","key":"10.1016\/j.pharmthera.2021.107931_bb0540","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science (New York, N.Y.)"},{"key":"10.1016\/j.pharmthera.2021.107931_bb0545","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03431-4","article-title":"Clofazimine broadly inhibits coronaviruses including SARS-CoV-2","author":"Yuan","year":"2021","journal-title":"Nature"},{"issue":"6515","key":"10.1016\/j.pharmthera.2021.107931_bb0550","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"7843","key":"10.1016\/j.pharmthera.2021.107931_bb0555","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-020-2943-z","article-title":"COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice","volume":"589","author":"Zheng","year":"2021","journal-title":"Nature"},{"issue":"7852","key":"10.1016\/j.pharmthera.2021.107931_bb0560","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-021-03361-1","article-title":"SARS-CoV-2 spike D614G change enhances replication and transmission","volume":"592","author":"Zhou","year":"2021","journal-title":"Nature"},{"issue":"7798","key":"10.1016\/j.pharmthera.2021.107931_bb0565","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107931_bb0570","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107931_bb0575","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2020.04.035","article-title":"SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues","volume":"181","author":"Ziegler","year":"2020","journal-title":"Cell"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:15:11Z","timestamp":1759011311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821001339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":115,"alternative-id":["S0163725821001339"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107931","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107931"}}